RxSight, Inc. (RXST) Securities Class Action Lawsuit Update [September 03, 2025]

Introduction to RxSight, Inc (RXST) Securities Lawsuit

Investors filed a federal lawsuit against RxSight, Inc. (NASDAQ: RXST). The case is for people who got RxSight stock between November 7, 2024, and July 8, 2025 (the “Class Period”). Plaintiffs say RxSight and some of its executives violated federal securities laws when they misled the public about demand for its light adjustable lens system. The lawsuit says RxSight hid adoption stalls that gutted sales and utilization.  

Plaintiffs assert RxSight spun a tale of surging enthusiasm, record metrics, and steady growth. The truth as far worse. Structural issues chewed away at business operations and prospects, while execs overstated demand . . . by a lot. The blur cleared and investors learned the truth (thanks to slashing a previously issued financial guidance and executive confessions). The stock cracked. Now, shareholders are suing to recover their losses.  

RxSight, Inc. (RXST) Securities Lawsuit Case Details  

Caption: Makaveev v. RxSight, Inc., et al. 

Case No.: 8:25-cv-01596 

Jurisdiction: U.S. District Court, Central District of California 

Filed on: July 22, 2025 

RxSight, Inc. (RXST) Company Profile  

RxSight builds medical technology for eye surgery. The company's primary product is called the RxSight system. It’s specially designed machine for cataract surgery. The RxSight system is made up of two parts. First, the Light Adjustable Lens (LAL), is an artificial lens implanted in the eye. Second is the Light Delivery Device (LDD), a machine that shines ultraviolet light to adjust the lens after surgery for sharper vision. RxSight says two devices together improve vision for people with cataracts. By late 2024, RxSight had placed 888 LDDs in clinics, with lens implantations driving its income. The company competes in a market for premium eye lenses worth billions, but the lawsuit claims it hit snags with getting doctors to use its system widely.

Class Period:  

November 7, 2024, to July 8, 2025 

People who acquired RxSight securities during the class period might be eligible to join the RxSight, Inc, securities fraud class action lawsuit. 

Allegations in the RxSight, Inc. (RXST) Securities Lawsuit

The complaint skewers RxSight and some of its execs (CEO Ron Kurtz and CFO Shelley Thunen) for hiding the truth about demand for RxSight’s system. Plaintiffs say that throughout the class period, defendants failed to disclose adoption challenges gnawing at sales and utilization; massively overstated product demand; set RxSight up to miss 2025 guidance. In the end, though, all that bluster was empty. 

On November 7, 2024 the company revealed its Q3 financials. Revenue was up an impressive 59% to $35.3 million. Demand was booming, too: LALs 24,554 (80% jump), LDDs 78 (18% more). In the shareholder call, Kurtz hailed "ongoing demand." The Company’s10-Q echoed that sentiment, touting "strong adoption."  

On January 12, 2025, the company revealed its Q4 and full-year financials. It offered a strong revenue guidance of $185-197 million. That bold prediction got confirmed on February 25, 2025.  RxSigh’s form 10-K again boasted about "strong adoption."  

In April 2025, the company trimmed its guidance to $160-175 million. That new guidance was affirmed in May. Plaintiffs allege these glowing statements about revenue and demand served to prop up RxSight’s stock price. But investors claim all this bluster was actually materially misleading and deceptive: RxSight’s executives knew things weren’t great, but hid the truth anyhow. Once the truth emerged, the stock’s price tanked, costing investors millions.     

The Truth Emerges  

Investors learned the truth on July 8, 2025, when RxSight revealed lackluster quarterly financials and a decline in sales. Revenue was down 4% year-over-year and 11% from the prior quarter. Demand for RxSight's products was down: LALs by 1% and LDDs down about 45%.   

The company axed its annual revenue guidance, slashing it to $120-130 million. Kurtz admitted "adoption challenges [are the] primary reason for the LDD stall." These drops and admissions were a stark contrast to the bold predictions made earlier in the year.  

Market Reaction  

Investors didn’t like what they heard once the veil lifted and discovered the bad news. On July 9, 2025 shares fell $4.84—a whopping 37.8%—closing at $7.95 on heavy volume.  

Next Steps  

• Submissions for lead plaintiff are due September 22, 2025. 
• The Court will issue its order for lead plaintiff and counsel in the weeks after submissions are due.    
• The Court will then consider motion for class certification.     
• The Court will later consider a Motion to Dismiss.    

To learn if you are eligible for recovery under the RxSight securities class action lawsuit, visit the case submission page here. 

Disclaimer: This shareholder alert is for informational purposes only and does not constitute legal advice. Consult a qualified attorney for personalized guidance. No specific outcomes are guaranteed.